Product Details:
Strength | 250 mg |
Manufacturer | Cipla |
Prescription/Non prescription | Prescription |
Composition | Lapatinib |
Brand | Combinib |
Packaging Size | 30 Tablets |
Form | Tablet |
Treatment | To treat HER2-positive breast cancer |
Country of Origin | Made in India |
Combinib Lapatinib 250 mg Tablet contains Lapatinib which belongs to the group of medicines called antineoplastic agent. It is used to treat HER2-positive breast cancer which have spread beyond the original tumor or to other organs (advanced or metastatic breast cancer).
HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which is capable of promoting the growth of cancer cells. Lapatinib is generally prescribed with other anti-cancer medicine like capecitabine, trastuzumab (for patients with hormone receptor-negative metastatic breast cancer) or aromatase inhibitor (for patients with hormone sensitive metastatic breast cancer). It slows or stops cancer cells from growing or may kill them.
Always take this medicine as directed by your physician. Take this medicine, either at least 1 hour before or 1 hour after food. Prior to the treatment, your doctor will check whether your heart and lungs are working properly or not.
Avoid consumption of alcohol while taking this medicine. Do not drive or operate any machines if your ability is affected by this medicine. Talk to your doctor immediately at the first sign of diarrhea, because it is important that this is treated right away. Do not take this medicine, if you have diarrhea, liver, kidney or lung problems or are pregnant. The most common side effect of taking this medicine is diarrhea, rash, dry skin, itching, loss of appetite, stomach pain, indigestion, constipation, nausea or vomiting, tiredness, mouth ulcers, trouble in sleeping, pain in hands and feet.